A randomized, open-label, multicenter, phase 2 clinical trial to explore the safety and efficacy of sepranolone in pediatric and adult patients with Tourette Syndrome.

Asarina Pharma ApS0 个研究点目标入组 30 人开始时间: 2021年3月24日最近更新: 2022年4月4日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Asarina Pharma ApS
入组人数: 30

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•Pediatric subjects:
•1)provide written informed consent prior to any study related procedures
•2)be diagnosed with Tourette syndrome according to the European diagnostic criteria that have been established by the European ESSTS Guidelines Group and based on the tenth International Classification of Disease (ICD-10) (Cath et al 2011).
•3)be either male or female
•4)be aged =12 and =17 years at the time of screening
•5)have a BMI of for adolescents normal for age ± 2SD (See appendix D)
•6)Have a tic severity at screening graded as moderate to severe, corresponding to a tic score of =20 on the Yale Global Tic Severity Scale Total Score (Leckman et al, 1998).
•7)The patient may have a comorbidity of Obsessive-Compulsive Disease (OCD) that, in the opinion of the Investigator, does not interfere with the evaluation of symptoms of the patient’s Tourette syndrome.
•8)No treatment or ongoing stable treatment of cognitive therapy and/or stable doses of any allowed chronic or PRN concomitant treatment during three months prior to entering of baseline phase, at the discretion of the investigator. Hormonal treatments are not allowed. See also Disallowed and restricted medications list (Appendix J).
•9)For a female subject of childbearing potential, agree to use sufficient contraception.
•10) For a male patient, he must:
•a.agree to use sufficient barrier contraception or be truly abstinent. He must also agree to continue sufficient contraception for three months after completing study treatment.
•11) for women of childbearing potential: a negative pregnancy test at Visit 1 and 3.
•for both child and parent/custodian, able to understand and communicate with the study doctor and staff.
•13) able to accept the use of injectable medication, adhere to the medication regimens and perform study procedures.
•14) for the child and parent/custodian, able to read and comprehend written instructions and be willing to complete all procedures and assessments required by this protocol.
•Adult Subjects:
•1)have given his/her written informed consent.
•2)be diagnosed with Tourette syndrome according to the European diagnostic criteria that have been established by the European ESSTS Guidelines Group and based on the tenth International Classification of Disease (ICD-10) (Cath et al 2011).
•3)be either male or female.
•4)be between =18 and =55 years at time the screening visit.
•5)have a BMI =18.5 kg/m2 or =32 kg/m2.
•6)Have a tic severity at screening graded as moderate to severe, corresponding to a tic score of =20 on the Yale Global Tic Severity Scale Total Score (Leckman et al, 1998).
•7)The patient may have a comorbidity of Obsessive-Compulsive Disease (OCD) that, in the opinion of the Investigator, does not interfere with the evaluation of symptoms of the patient’s Tourette syndrome.
•8)No treatment or ongoing stable treatment of cognitive therapy and/or stable doses of any allowed chronic or PRN concomitant treatment during three months prior to entering of baseline phase, at the discretion of the investigator. Hormonal treatments are not allowed. See also Disallowed and restricted medications list (Appendix J).
•9)For a female subject of childbearing potential, agree to use sufficient contraception.
•10) For a male patient, he must:
•a.agree to use sufficient barrier contraception or be truly abstinent. He must also agree to continue sufficient contraception for three months after completing study treatment.
•11) for women of childbe

排除标准

•Pediatric subjects:
•1)has participated in a clinical study and received active drug in such a study within 30 days or 5 study drug half-lives, whichever the longest, prior to the first study visit.
•2)has, in the investigator's opinion, evidence and/or history of any clinically significant neurological disease, or other conditions potentially interfering with study assessments.
•3)has or has had a malignant disease.
•4)has a history of other unstable or clinically significant medical condition that in the opinion of the investigator that would pose a risk to the subject safety or interfere with study evaluation, including e.g. unstable cardiovascular disease, uncontrolled diabetes, unstable thyroid disease, renal impairment or hepatic impairment (Gilbert syndrome allowed).
•5)has HIV or ongoing hepatitis.
•6)has any clinically significant findings in vital signs, laboratory results, or ECG that in the opinion of the investigator would pose a risk to the subject safety or interfere with study evaluation.
•7)has allergies to ingoing study drug components or a history of true anaphylactic reactions.
•8)have had a blood loss =250 mL within 56 days prior to screening.
•9)is pregnant or breast-feeding, or planning pregnancy during the study period.
•10) has an unstable major psychiatric disorder according to DSM 5® criteria.
•11) has a history of drug abuse or dependency that in the judgement of the investigator may interfere with study compliance.
•12) is taking hormonal contraceptives (hormonal IUD is allowed). For injectable hormonal contraceptives, a 6-month washout is required.
•taking disallowed medications or allowed with restrictions with respect to their use prior to or during the full study period (this list is not comprehensive).
•13) taking disallowed medications or allowed with restrictions with respect to their use prior to or during the full study period (this list is not comprehensive).
•14) the subject or parent/custodian is a member of investigational site staff or relative of the investigator.
•Adult subjects:
•1)has participated in a clinical study and received active drug in such a study within 30 days or 5 study drug half-lives, whichever the longest, prior to the first study visit.
•2)has, in the investigator's opinion, evidence and/or history of any clinically significant neurological disease, or other conditions potentially interfering with study assessments.
•3)has or have had a malignant disease within the previous 5 years (except non-melanoma skin cancer, cervical or breast ductal carcinoma in situ).
•4)has a history of other unstable or clinically significant medical condition that in the opinion of the investigator would pose a risk to the subject safety or interfere with study evaluation, including e.g. unstable cardiovascular disease, uncontrolled diabetes, unstable thyroid disease, renal impairment or hepatic impairment (Gilbert syndrome allowed).
•5)has HIV or ongoing hepatitis.
•6)has any clinically significant findings in vital signs, laboratory results, or ECG that in the opinion of the investigator would pose a risk to the subject safety or interfere with study evaluation.
•7)has allergies to ingoing study drug components or a history of true anaphylactic reactions.
•8)have a blood loss =550 mL or donated blood within 30 days prior to screening.
•9)is pregnant or breast-feeding, or planning pregnancy during the study period.
•10) has an unstable major psychiatric disorder according

研究者

发起方

Asarina Pharma ApS

相似试验

进行中（未招募）

1 期

An open-label, randomized, multicenter, phase II trial designed to estimate the activity of CAPTEM combination versus FOLFIRI as second line treatment in patients who have progressed on or after first-line oxaliplatin - containing chemotherapy for advanced, MGMT methylated, RAS mutated colorectal cancerMedDRA version: 17.0Level: HLTClassification code 10008442Term: ChemotherapiesSystem Organ Class: 100000004865MedDRA version: 17.0Level: LLTClassification code 10069759Term: KRAS mutationSystem Organ Class: 100000004867colorectal cancer

EUCTR2014-002417-36-ITFondazione IRCCS Istituto Nazionale dei Tumori82

进行中（未招募）

不适用

APG101 in glioblastomaGlioblastoma Multiforme (first or second progression)MedDRA version: 14.1Level: PTClassification code 10018336Term: GlioblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10018337Term: Glioblastoma multiformeSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2009-013421-42-DEApogenix GmbH83

进行中（未招募）

不适用

EUCTR2009-013421-42-ATApogenix GmbH83

进行中（未招募）

1 期

A study to compare the treatment of Vinblastine alone or in combination with Bevacizumab in children with progressive low grade glioma (LGG).

EUCTR2017-001982-26-GBThe Hospital for Sick Children150

进行中（未招募）

1 期

Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease PatientsSickle Cell Disease/ Iron Overload

EUCTR2016-002583-14-Outside-EU/EEAovartis Pharmaceuticals Corp210